Clinical trials: Systemic Sclerosis, Diffuse
Scleroderma, Systemic Sclerosis
Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma
To investigate the ability of divalproex sodium, a histone deacetylase inhibitor, to improve the digital manifestations of scleroderma including digital edema, calcinosis cutis, digital ulcers, and joint contractures.
- Trial name
- NCT02166229
- Testing
- Divalproex sodium
- Where
- United States
- Sponsor
- Yale University
Scleroderma
Connective Tissue Massage in Scleroderma
The only study in the literature that examined connective tissue massage in patients with scleroderma is by Bongi et al. In this study, connective tissue massage and Mc Mennell joint manipulation technique were applied to the…
- Trial name
- NCT06474910
- Testing
- Connective tissue massage, Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Firat University
Diffuse Cutaneous Systemic Sclerosis
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
This is a multicenter, open-label study to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive Diffuse Cutaneous Systemic Sclerosis (dcSSc) at risk for organ…
- Trial name
- FREEDOM-3 (NCT05098145)
- Testing
- FCR001
- Where
- United States
- Sponsor
- Talaris Therapeutics Inc.
Scleroderma, Scleroderma, Systemic
Effectiveness of Telerehabilitation on Scleroderma
The effects of exercises performed by telerehabilitation on individuals with hand-affected scleroderma on range of motion, grip strength, function, sensation, daily life activities and general health will be compared with the…
- Conditions
- Scleroderma, Scleroderma, Systemic, Scleroderma Associated Digital Ulcer, Hand Rheumatism
- Trial name
- NCT04563481
- Testing
- Hand Therapy via Telerehabilitation, Hand Therapy by Physiotherapist
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Istanbul University
Systemic Sclerosis (Scleroderma)
Treatment of Early Systemic Sclerosis by Bosentan
Systemic sclerosis (ssc) is characterised by extensive tissue fibrosis. Using drugs that are capable of inhibiting fibroblast activity may be beneficial if administrered early in the disease course.
- Trial name
- TRANOS (NCT00226889)
- Testing
- bosentan
- Where
- Norway
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rikshospitalet University Hospital
Scleroderma, Systemic
Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.
Systemic sclerosis is an autoimmune disease in which the hand is responsible for 75% of the overall disability. Management is based on systemic treatments combined with kinesitherapy aimed at maintaining joint amplitudes…
- Trial name
- SCLERO-HAND (NCT05171114)
- Testing
- Measurement of joint amplitudes
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Limoges
Scleroderma
Scleroderma Registry & Repository at the Hospital for Special Surgery
The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS).
- Trial name
- NCT01656447
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Scleroderma
Delving Into Participation Trends of Scleroderma Clinical Trials
Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular…
- Trial name
- NCT06264492
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Diffuse Cutaneous Systemic Sclerosis
Mycophenolate Mofetil in Systemic Sclerosis
This is a research study of an investigational product called Mycophenolate mofetil (MMF). The study is designed to establish the safety and potential benefit of MMF.
- Trial name
- NCT00433186
- Testing
- Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Boston University
Scleroderma, Cardiac Involvement
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
Autologous stem cell therapy has been shown to be effective in patients with systemic sclerosis. Nevertheless treatment is associated with treatment related mortality and patients die during follow up despite successful…
- Conditions
- Scleroderma, Cardiac Involvement, Autologous Stem Cell Transplantation
- Trial name
- AST-MOMA (NCT01895244)
- Testing
- Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- University Hospital Tuebingen
Systemic Sclerosis, Scleroderma
Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease
Systemic sclerosis (SSc) is characterized by autoimmunity and vasculopathy resulting in fibrosis of the skin and internal organs including the Gastrointestinal (GI) tract.
- Trial name
- Pre Med SSc GI (NCT04630782)
- Testing
- PET-MRI scan
- Where
- 5 sites in Singapore
- Volunteers
- 70 people
- Sponsor
- Singapore General Hospital
Systemic Vasculitis, Spondylarthropathies
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD)…
- Conditions
- Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis, Scleroderma
- Trial name
- HZ-REUMA (NCT06763783)
- Testing
- Shingrix, vaccination with 2 doses of Shingrix vaccine
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Region Skane
Scleroderma Disease
Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases
This is a phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ® Polydeoxyribonucleotide i.m.
- Trial name
- NCT03388255
- Testing
- Polydeoxyribonucleotides
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Mastelli S.r.l
Systemic Sclerosis (SSc)
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial.
- Trial name
- ASScERT-QoL (NCT06675344)
- Testing
- Apollo Neuro Device
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Skeletal Muscle Function in Interstitial Lung Disease
Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why.
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Scleroderma
- Trial name
- NCT03800017
- Testing
- Hyperoxia
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Scleroderma
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
- Trial name
- NCT00764309
- Testing
- dasatinib
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- Bristol-Myers Squibb
Scleroderma
Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
The purpose of this study is to investigate the effectiveness and safety of the drug Gleevec (imatinib) as a new treatment for patients with active diffuse scleroderma.
- Trial name
- NCT01545427
- Testing
- Imatinib mesylate
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Olfactory Disorders, Scleroderma
Assessment of the Prevalence of Olfactory Disorders in Systemic Scleroderma
Prospective monocentric study of patients with systemic sclerosis disease. The primary outcome is to define the prevalence of olfactory disorders (hyposmia and anosmia) in systemic sclerosis disease.
- Trial name
- SCLEROLF (NCT04178616)
- Testing
- olfactory testing with specific odorants (localisation and identification)
- Where
- France
- Volunteers
- 59 people
- Sponsor
- University Hospital, Lille
Lupus Erythematosus, Scleroderma
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be…
- Conditions
- Lupus Erythematosus, Scleroderma, Myositis, Vasculitis
- Trial name
- ESSAi (NCT05251415)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- University Hospital, Toulouse
Autoimmune Disease
Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study
Autoimmune diseases may involve nearly any organ and are characterized by abnormal activation or response of certain cells. Evidence suggests that farm work, exposure to silica from farming activities and exposure to pesticides…
- Trial name
- NCT00341198
- Where
- 3 sites in United States
- Volunteers
- 700 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)